Form 4: Abbott Labs Director Roman Acquires Stock Units

Michael F. Roman, a Director at Abbott Laboratories, acquired stock equivalent units valued at $90.74 per unit on June 30, 2026, as reported in a Form 4 filing.

Summary

• Michael F. Roman, a Director of Abbott Laboratories, acquired 416 stock equivalent units on June 30, 2026.
• These units were acquired as director fees and are valued at $90.74 per unit.
• The stock equivalent units earn returns equivalent to investing in Abbott shares.
• Following this transaction, Roman beneficially owns 6,746 stock equivalent units.
• The filing also notes that the balance includes units acquired through a dividend reinvestment feature.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine transaction related to director compensation rather than a significant strategic event or financial performance indicator.

Positives

• Director Michael F. Roman has increased his beneficial ownership of Abbott Laboratories stock equivalent units.
• The acquisition of stock equivalent units indicates continued alignment of management and director interests with shareholders.
• The dividend reinvestment feature suggests a mechanism for compounding returns on director compensation.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider transactions, such as this acquisition of stock equivalent units by a director, are common in the healthcare and pharmaceuticals sector as a way to align executive and director compensation with shareholder value.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively as a sign of confidence in the company's future performance, though it is part of standard compensation.

Key Dates

Keywords

Abbott Laboratories, Form 4, Stock Equivalent Units, Director Fees, Beneficial Ownership, Michael F. Roman, Insider Transaction, SEC Filing